Jasper Therapeutics, Inc.
About Jasper Therapeutics, Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$75.8M
- Total assets
- $35.8M
- Market cap
- $13.8M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Cost of revenue
- $41.6M
- Operating expenses
- $83.9M
- Operating income
- -$83.9M
- Net income
- -$75.8M
- EPS (basic)
- $-3.95
- EPS (diluted)
- $-3.95
Balance sheet
- Total assets
- $35.8M
- Current assets
- $34.6M
- Total liabilities
- $31.6M
- Current liabilities
- $13.2M
- Shareholders’ equity
- $4.2M
Cash flow
- Operating cash flow
- -$77.2M
- Investing cash flow
- $5.0K
- Financing cash flow
- $34.2M
- Net cash flow
- -$42.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.8M
- EPS (diluted)
- $-3.95
- Shares outstanding
- 29.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 27, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $75.8M.
- Trading 93% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Jasper Therapeutics, Inc..
Write a review
News about Jasper Therapeutics, Inc.
News & sentiment via Polygon.io
